In a preclinical model, at low doses, GDC-9545 promotes tumor regressions either as a single agent or combined with a CDK4/6 inhibitor in an ESR1 Y537S mutant PDX and in a wild-type ERα breast tumor model [112]. Here, ESR1 is linked to breast neoplasm.